NOVAVAX INC (NVAX) vs PFIZER INC (PFE)
Side-by-side comparison from SEC filings: latest annual financials, insider activity and institutional ownership.
| Metric | NVAX | PFE |
|---|---|---|
| Sector | Health Care | Health Care |
| Latest fiscal year | FY2025 | FY2025 |
| Revenue | $1.12B | $62.58B |
| Revenue growth (YoY) | ▲ 64.7% | ▼ 1.6% |
| Net income | $440.3M | $7.77B |
| Gross margin | 93.5% | 74.3% |
| Diluted EPS | $2.58 | $1.36 |
| Insider net (6 mo) | +113.3K sh • 0 sells • 0 buys | +109.6K sh • 2 sells • 3 buys |
| Institutional owners | 43 | 55 |
| Institutional value held | $830.11M | $62.67B |
| Next earnings (est.) | Around Feb 25, 2027 | Feb 2, 2027 |
Figures from each company's SEC filings (latest reported fiscal year; fiscal calendars may differ). Next-earnings dates are estimates from historical filing patterns.
About NOVAVAX INC (NVAX)
Novavax, Inc. is a vaccine company, incorporated in Delaware in 1987, that develops vaccines using a recombinant protein-based nanoparticle technology and its proprietary Matrix-M adjuvant. Read more →
About PFIZER INC (PFE)
Pfizer Inc. is a research-based global biopharmaceutical company, incorporated in Delaware in 1942. Read more →
Source: SEC EDGAR.